Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 20, 2022

SELL
$57.72 - $65.01 $7.06 Million - $7.95 Million
-122,288 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$57.92 - $72.58 $395,535 - $495,648
6,829 Added 5.91%
122,288 $7.27 Million
Q4 2021

Feb 02, 2022

BUY
$64.88 - $73.64 $544,343 - $617,839
8,390 Added 7.84%
115,459 $8.38 Million
Q3 2021

Nov 05, 2021

BUY
$67.69 - $73.03 $7.25 Million - $7.82 Million
107,069 New
107,069 $7.48 Million
Q3 2020

Nov 12, 2020

SELL
$62.1 - $78.08 $1.42 Million - $1.79 Million
-22,868 Closed
0 $0
Q2 2020

Aug 11, 2020

SELL
$72.34 - $84.0 $3.04 Million - $3.53 Million
-42,063 Reduced 64.78%
22,868 $1.76 Million
Q1 2020

May 14, 2020

SELL
$62.63 - $80.22 $3,382 - $4,331
-54 Reduced 0.08%
64,931 $4.85 Million
Q4 2019

Feb 11, 2020

BUY
$61.62 - $67.78 $260,344 - $286,370
4,225 Added 6.95%
64,985 $4.22 Million
Q3 2019

Nov 12, 2019

BUY
$62.51 - $69.0 $3.8 Million - $4.19 Million
60,760 New
60,760 $3.85 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track O'Shares Investment Advisers, LLC Portfolio

Follow O'Shares Investment Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of O'Shares Investment Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on O'Shares Investment Advisers, LLC with notifications on news.